Studies conducted by physicians at Florida Cancer Specialists & Research Institute were featured in poster presentations at ASCO 2022 Gastrointestinal Cancers Symposium.
Fort Myers, Florida — Studies conducted by physicians at Florida Cancer Specialists & Research Institute (FCS) were featured in poster presentations at American Society of Clinical Oncology (ASCO) 2022 Gastrointestinal Cancers Symposium held in San Francisco, California from January 20-22, 2022.
The abstract “Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with advanced colorectal cancer (CRC),” includes observations from FCS physicians, Ivor Percent, MD, Maen Hussein, MD, and Viralkumar Bhanderi, MD, who were co-authors.
This Phase II study, evaluating the effectiveness of an anti-PD-1 antibody, combined with other agents, found antitumor activity comparable to third-line therapy for this patient population.
“The ability to be involved in cutting edge treatments in my private practice that are saving lives is an innovative approach that has touched so many, saved and changed lives, and moved medicine forward,” said Percent, who is a hematologist and medical oncologist at FCS.